Item 2. Management’s Discussion and Analysis
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
References
in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to AGBA
Acquisition Limited. References to our “management” or our “management team” refer to our officers and directors,
references to the “Sponsor” refer to AGBA Holding Limited. The following discussion and analysis of the Company’s financial
condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and
the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth
below includes forward-looking statements that involve risks and uncertainties.
Special
Note Regarding Forward-Looking Statements
This
Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to
differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q
including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for
future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,”
“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s
current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ
materially from the events, performance and results discussed in the forward-looking statements. For information identifying important
factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to
the Risk Factors section of the Company’s registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission
(the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov.
Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We
are a blank check company incorporated in the British Virgin Islands on October 8, 2018 and formed for the purpose of entering into a
merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one
or more businesses or entities.
We
presently have no revenue, have had losses since inception from incurring formation costs and have had no operations other than the active
solicitation of a target business with which to complete a business combination. We have relied upon the sale of our securities and loans
from our officers and directors to fund our operations.
On
May 16, 2019, the Company consummated its initial public offering of 4,600,000 units, which includes the full exercise of the over-allotment
option. Each Public Unit consists of one ordinary share, one redeemable warrant, and one right to receive one-tenth (1/10) of an ordinary
share upon the consummation of an initial business combination. Each redeemable warrant entitles the holder thereof to purchase one-half
(1/2) of one ordinary share, and each ten rights entitle the holder thereof to receive one ordinary share at the closing of a business
combination. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $46,000,000. Simultaneously with
the closing of the initial business combination, the Company consummated the private placement of 225,000 units at a price of $10.00
per Private Unit, generating total proceeds of $2,250,000. A total of $46,000,000 of the net proceeds from the sale of Public Units in
the initial business combination (including the over-allotment option units) and the private placements were placed in a Trust Account
established for the benefit of the Company’s public shareholders. The Company incurred $2,559,729 in initial public offering related
costs, including $2,175,948 of underwriting fees and $383,781 of initial public offering costs.
We
will not issue fractional shares. As a result, one must (1) exercise warrants in multiples of two warrants, at a price of $11.50 per
full share, to validly exercise the warrants; and (2) hold rights in multiples of 10 in order to receive shares for all of the rights
upon closing of a business combination.
23
On
each of May 11, August 13 and November 10, 2020, we issued a $460,000 unsecured promissory note to the Sponsor, pursuant to which such
amount was deposited into our Trust Account in order to extend the amount of time we had available to complete a business combination
from May 16, 2020 to February 16, 2021. On each of February 10, May 11 and August 11, 2021, the Company issued an unsecured promissory
note, in an amount of $594,467, to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend
the amount of available time to complete a business combination until November 16, 2021. On each of November 10, 2021 and February 7,
2022, the Company issued an unsecured promissory note in an amount of $546,991, to the Sponsor, pursuant to which such amount had been
deposited into the Trust Account in order to extend the amount of available time to complete a business combination until May 16, 2022.
Each of these promissory notes is non-interest bearing and is payable upon the closing of a business combination. In addition, each of
the promissory notes may be converted, at the lender’s discretion, into additional Private Units at a price of $10.00 per unit.
We
held our annual meeting of shareholders on May 3, 2022 (the “2022 Annual Meeting”). During the 2022 Annual Meeting,
shareholders approved, among other things, (i) the Fourth Amended and Restated Memorandum and Articles of Association to extend the
date by which the Company has to consummate a business combination two times for three additional months each time from May 16, 2022
to November 16, 2022; (ii) an amendment to the Company’s investment management trust agreement, dated May 14, 2019, as
amended, by and between the Company and Continental Stock Transfer & Trust Company to extend the time to complete a business
combination to November 16, 2022; and (iii) elected all of the five nominees for directors to serve until the next annual meeting of
shareholders approved. On each of May 9, 2022, and August 9, 2022, we issued an unsecured promissory note, in an amount of $504,431
to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available
time to complete a business combination until November 16, 2022.
Our
management has broad discretion with respect to the specific application of the net proceeds of the initial business combination and
the private placement, although substantially all of the net proceeds are intended to be applied generally towards consummating a business
combination.
The
outbreak of the COVID-19 coronavirus has resulted in a widespread health crisis that has adversely affected the economies and financial
markets worldwide, and potential target companies may defer or end discussions for a potential business combination with us whether or
not COVID-19 affects their business operations. The extent to which COVID-19 impacts our search for a business combination will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the
severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. We may be unable to complete a business combination
if continued concerns relating to COVID-19 restrict travel, limit the ability to have meetings with potential investors or the target
company’s personnel, vendors and services providers are unavailable to negotiate and consummate a transaction in a timely manner.
On
November 3, 2021, the Company entered into the business combination Agreement, which provides for a business combination between AGBA
and TAG and certain of TAG’s wholly owned subsidiaries – OPH, Fintech, B2B, B2BSub, and HKSub. OPH through its wholly-owned
subsidiaries, is engaged in business-to-business (or B2B) services, while Fintech through its wholly-owned subsidiaries, is engaged in
the financial technology or fintech business. B2BSub is a wholly-owned subsidiary of B2B, and HKSub is a wholly owned subsidiary of B2BSub.
In the business combination agreement, as amended, B2B, B2BSub, HKSub, OPH, Fintech, together with their respective subsidiaries are
referred to as the “Group Parties”. Pursuant to the business combination agreement, as amended, OPH will first become a subsidiary
of B2B through a merger with HKSub, with OPH as the surviving entity (the “OPH Merger”). Subsequently, (i) AMSI will merge
with and into B2B; and AMSII will merge with and into Fintech (together with (i), the “Acquisition Merger”). In consideration
of the Acquisition Merger, AGBA will issue 55,500,000 ordinary shares with a deemed price per share US$10.00 (“Aggregate Stock
Consideration”) to TAG, in its capacity as sole shareholder of B2B and Fintech.
24
At
the closing of the Acquisition Merger, AGBA shall issue the full amount of the Aggregate Stock Consideration, less three percent (3%)
of the Aggregate Stock Consideration (the “Holdback Shares”), to TAG, in its capacity as sole shareholder of B2B and Fintech,
subject to compliance with applicable law. Subject to the provisions of the business combination Agreement, AGBA will release the Holdback
Shares at the end of six (6) months following the closing of the Acquisition Merger, which may be extended for an additional three-month
period (the “Survival Period”), provided that the AGBA will be entitled to retain some or all of the Holdback Shares to satisfy
certain indemnification claims during the Survival Period. Post-closing, TAG intends to further distribute the Aggregate Stock Consideration
to certain beneficial shareholders of TAG, subject to legal and regulatory requirements.
Results
of Operations
Our
entire activity from inception up to May 16, 2019 was in preparation for the initial public offering. Since the initial public offering,
our activity has been limited to the evaluation of business combination candidates and engaging in activities in connection with the
proposed business combination transaction with TAG, and we will not be generating any operating revenues until the closing and completion
of our business combination.
For
the three months ended June 30, 2022, we had a net loss of $231,350, which was comprised of dividend income and general and administrative
expenses, as well as a loss from the change in fair value of warrant liabilities.
For
the three months ended June 30, 2021, we had a net loss of $174,441, which was comprised of general and administrative expenses and a
loss from change in fair value of warrant liabilities.
For
the six months ended June 30, 2022, we had a net loss of $583,086, which was comprised of interest and dividend income and general and
administrative expenses, as well as a loss from the change in fair value of warrant liabilities.
For
the six months ended June 30, 2021, we had a net loss of $306,245, which was comprised of general and administrative expenses and a loss
from change in fair value of warrant liabilities.
Liquidity
and Capital Resources
As
of June 30, 2022, we had cash of $85,619 outside our Trust Account available for working capital needs. All remaining cash was held in
the Trust Account and is generally unavailable for our use, prior to the business combination.
On
May 16, 2019, we consummated the initial public offering of 4,600,000 Public Units (which includes the full exercise of the underwriter’s
over-allotment option), at a price of $10.00 per unit, generating gross proceeds of $46,000,000. Simultaneously with the closing of the
initial public offering, we consummated the sale of 225,000 Private Units, at a price of $10.00 per unit, generating gross proceeds of
$2,250,000.
Following
the initial public offering and the exercise of the over-allotment option, a total of $46,000,000 was placed in the Trust Account. We
incurred $2,559,729 in initial public offering related costs, including $2,175,948 of underwriting fees and $383,781 of initial public
offering costs.
Our
liquidity needs have been satisfied to date through receipt of $25,000 from the sale of the insider shares, note payable of $4,761,812
and advances from our Sponsor in an aggregate amount of $1,419,337 outstanding as of June 30, 2022, and the remaining net proceeds from
our initial public offering and private placement.
We
intend to use substantially all of the net proceeds of the initial public offering, including the funds held in the Trust Account, to
acquire a target business or businesses and to pay our expenses relating thereto. To the extent that our capital stock is used in whole
or in part as consideration to effect our business combination, the remaining proceeds held in the Trust Account, as well as any other
net proceeds not expended, will be used as working capital to finance the operations of the target business. Such working capital funds
could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic acquisitions
and for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses
or finders’ fees which we had incurred prior to the completion of our business combination if the funds available to us outside
of the Trust Account were insufficient to cover such expenses.
25
We
intend to use the funds held outside the Trust Account primarily for activities relating to consummating the proposed business combination
with TAG.
If
our estimates of the costs of consummating our proposed business combination is less than the actual amount necessary to do so, or the
amount of interest available to us from the Trust Account is less than we expect as a result of the current interest rate environment,
we may have insufficient funds available to operate our business prior to our initial business combination. Moreover, we may need to
obtain additional financing either to consummate our initial business combination or because we become obligated to redeem a significant
number of our public shares upon consummation of our initial business combination, in which case we may issue additional securities or
incur debt in connection with such business combination. Subject to compliance with applicable securities laws, we would only consummate
such financing simultaneously with the consummation of our initial business combination. Following our initial business combination,
if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations, and there is no assurance
that such financing can be obtained on favorable terms, or at all.
We
may need to seek additional capital through loans or additional investments from members of our management team, but such members of
our management team are not under any obligation to advance funds to, or invest in, us. In the event that the business combination does
not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from
our Trust Account would be used for such repayment. Such loans would be evidenced by promissory notes. The notes would either be paid
upon consummation of our business combination, without interest, or, at the lender’s discretion, up to $500,000 of the notes may
be converted upon consummation of our business combination into additional Private Units at a price of $10.00 per unit. The terms of
such loans by our initial shareholders, officers and directors, if any, have not been determined and no written agreements exist with
respect to such loans.
Accordingly,
the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required
to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending
the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will
be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability
to continue as a going concern if a business combination is not consummated by November 16, 2022. These unaudited condensed consolidated
financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities
that might be necessary should the Company be unable to continue as a going concern.
Off-balance
Sheet Financing Arrangements
We
have no obligations, assets or liabilities which would be considered off-balance sheet arrangements as of June 30, 2022. We do not participate
in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest
entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into
any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities,
or purchased any non-financial assets.
Contractual
Obligations
We
do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities other than an agreement
to pay our Sponsor a monthly fee of $10,000 for general and administrative services, including office space, utilities and administrative
services to the Company. We began incurring these fees on May 16, 2019 and will continue to incur these fees monthly until the earlier
of the completion of the business combination and the Company’s liquidation. Also, we are committed to the below:
Registration
Rights
The
holders of our insider shares issued and outstanding prior to our initial public offering, as well as the holders of the Private Units
(and all underlying securities) and any securities our initial shareholders, officers, directors or their affiliates may be issued in
payment of working capital loans made to us, are entitled to registration rights pursuant to a registration rights agreement entered
into concurrently without initial public offering. In addition, the holders have certain “piggy-back” registration rights
with respect to registration statements filed subsequent to our consummation of a business combination. We will bear the expenses incurred
in connection with the filing of any such registration statements.
Underwriting
Agreement
The
underwriter is entitled to a cash underwriting discount of six and half percent (6.5%), or $0.65 per unit, of the gross proceeds of the
initial public offering. Two and one-half percent (2.5%), or $0.25 per share, is not contingent and has been paid at the closing of the
initial public offering. Four percent (4.0%), or $0.40 per unit, is contingent on the closing of a business combination and will be deferred
by the underwriters and be placed in the Trust Account. Such deferred amount will only be payable to the underwriters upon closing of
a business combination. Further, the deferred amount paid to the underwriters upon the closing of a business combination will be reduced
by two percent (2.0%), or $0.20 per unit, for each unit that is redeemed by shareholders in connection with the business combination.
If the business combination is not consummated, the deferred amount will be forfeited by the underwriters. The underwriters will not
be entitled to any interest accrued on the deferred amount.
26
Private
Warrants
The
Company classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting
period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized
in our statement of operations. The private warrants are valued using a Black Scholes model.
Unit
Purchase Option
The
Company sold to Maxim for $100, an option to purchase 276,000 units exercisable, at $11.50 per unit, between the first and fifth anniversary
of the effective date of the registration statement relating to our initial public offering. The purchase option may be exercised for
cash or on a cashless basis, at the holder’s option, and expires on May 13, 2024. The Company accounted for the unit purchase option,
inclusive of the receipt of $100 cash payment, as an expense of the Public Offering resulting in a charge directly to shareholders’
equity. The Company estimates that the fair value of the unit purchase option is approximately $747,960, or $2.71 per Unit, using the
Black-Scholes option-pricing model. The fair value of the unit purchase option granted to the underwriters is estimated as of the date
of grant using the following assumptions: (1) expected volatility of 35%, (2) risk-free interest rate of 2.18% and (3) expected life
of four years between first and fifth anniversary dates of the Effective Date. The option and the units, as well as the ordinary shares
and warrants to purchase ordinary shares that may be issued upon exercise of the option, have been deemed compensation by FINRA and are
therefore subject to a lock-up for a period of 180 days immediately following the effective date of the registration statement for our
initial public offering pursuant to Rule 5110(g)(1) of FINRA’s rules, during which time the option may not be sold, transferred,
assigned, pledged or hypothecated, or be subject of any hedging, short sale, derivative or put or call transaction that would result
in the economic disposition of the securities. Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated
prior to May 13, 2020 except to any underwriters and selected dealer participating in the offering and their bona fide officers or partners.
The option grants to holders demand and “piggy back” rights for periods of five and seven years, respectively, from the effective
date of the registration statement of which forms a part with respect to the registration under the Securities Act of the securities
directly and indirectly issuable upon exercise of the option. We will bear all fees and expenses attendant to registering the securities,
other than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of units issuable
upon exercise of the option may be adjusted in certain circumstances including in the event of a share dividend, or our recapitalization,
reorganization, merger or consolidation. However, the option will not be adjusted for issuances of ordinary shares at a price below its
exercise price.
Right
of First Refusal
Subject
to certain conditions, the Company granted Maxim, for a period of 18 months after the date of the consummation of the business combination,
a right of first refusal to act as lead underwriters or minimally as a co-manager, with at least 30% of the economics; or, in the case
of a three-handed deal, 20% of the economics, for any and all future public and private equity and debt offerings. In accordance with
FINRA rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of
the registration statement for our initial public offering.
Critical
Accounting Policies
The
preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles
generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed
consolidated financial statements, and income and expenses during the periods reported. Actual results could materially differ from those
estimates. The Company has not identified any significant accounting policies.
Ordinary
Shares Subject To Possible Redemption
The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “ Distinguishing
Liabilities from Equity .” Ordinary share subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are
either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s
control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s
ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence
of uncertain future events.
27
Net
Income (Loss) Per Share
The
Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share
is computed by dividing the net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary
shares subject to possible conversion. Diluted loss per share is computed by dividing net loss by the weighted average number of ordinary
shares outstanding, plus to the extent dilutive, the incremental number of ordinary shares to settle rights and other ordinary share
equivalents (currently none outstanding), as calculated using the treasury stock method. Ordinary shares subject to possible conversion
at June 30, 2022, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of
basic and diluted loss per share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings.
The Company has not considered the effect of rights that convert into 276,000 ordinary shares in the unit purchase option sold to the
underwriter, in the calculation of diluted loss per share, since the conversion of the rights into ordinary is contingent upon the occurrence
of future events.
Warrant
Liabilities
The
Company accounts for the warrants in accordance with the guidance contained in ASC 815-40-15-7D and 7F under which the private warrants
do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the private warrants
as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period. This liability is subject
to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations.
The private warrants are valued using a Black Scholes model.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.